ReShape Lifesciences (Formally known as EnteroMedics)
2800 Patton Road
268 articles with ReShape Lifesciences (Formally known as EnteroMedics)
ReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device
ReShape Lifesciences Inc., (OTCQB: RSLS) a global weight-loss solutions leader, today announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation™ (DBS
ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the three months ended June 30, 2020.
ReShape Lifesciences to Report Second Quarter 2020 Financial and Operational Results on Thursday, August 13, 2020
ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced that it will report its second quarter 2020 financial and operational results on Thursday, August 13, 2020 after the close of the U.S. financial markets.
ReShape Lifesciences Recognizes National Parents' Day Offering New Resources for Women Considering Weight-Loss and Parenthood
ReShape Lifesciences Inc., (OTCQB:RSLS) announced today that in recognition of National Parents' Day, it is providing updated information resources for women considering pregnancy that want to safely lose excess weight and experience the joy of parenthood.
ReShape Lifesciences and inHealth Lifestyle Therapeutics Launch ReShapeCare(TM) Virtual Health Coaching for Patients with Obesity
ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally-invasive medical devices to treat obesity and metabolic diseases, today announced a partnership with inHealth Lifestyle Therapeutics (formerly inHealth Medical Services), a Lifestyle Therapeutics company, to launch the ReShapeCare™ virtual health coaching program this month.
12/27/2018Researchers at the University of Wisconsin-Madison have developed a battery-free, easily implantable device, about a third the size of a penny, that helped laboratory rats lose weight.
Apollo Endosurgery, Inc., today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc.
ReShape Lifesciences Inc. announced the Company has commenced site initiation training for the first clinical trial site that will participate in the multi-center trial of the ReShape VestTM to support CE Mark approval.
ReShape Lifesciences Inc. (Nasdaq:RSLS), today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock.
ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston
ReShape Lifesciences Inc. announced the successful implant of the first ReShape Balloon™ at the Brigham and Women's Hospital in Boston, MA.
The company has had an abstract accepted by the scientific committee of the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
ReShape Lifesciences Inc. announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity,"
ReShape Lifesciences Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 374,572 shares of its common stock, at a purchase price per share of $3.92
ReShape Lifesciences Inc. announced the formation of the Company's Scientific Advisory Board (SAB)
ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio
Patent is directed to a combination of blocking and stimulating the vagus and celiac nerve branches using specific bioelectronic parameters to treat gastrointestinal disorders, including obesity, diabetes, and various combinations thereof.
ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons
ReShape Lifesciences Inc. provided an explanation and clarifying details to a letter dated June 4, 2018 that the U.S. Food and Drug Administration (FDA) posted on their website addressed to Health Care Providers.
ReShape Lifesciences Inc. announced that its Board of Directors has declared a 1-for-15 reverse stock split of the company's common stock
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company will be exhibiting and participating at Digestive Disease Week (DDW), which is taking place from June 2-5, 2018 at the Walter E. Washington Convention Center in Washington, DC.
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the submission of an application to the Medical Devices Bureau of the Therapeutic Products Directorate in Canada that seeks to amend the Company's existing Canadian medical device license to include distribution of the Company's current generation ReShape Balloon™ and associated accessories.
ReShape Lifesciences Inc. announced that it will host a conference call to discuss financial results for the first quarter 2018 on Monday, May 14, 2018 at 1:30 PM Pacific Time.